TORONTO, ONTARIO--(Marketwired - Dec. 14, 2016) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective January 1, 2017. Spectral's Common shares will continue to be listed on the Toronto Stock Exchange.
About Spectral Medical Inc.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product Toraymyxin™ ("PMX") for the treatment of patients with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Currently there is no specific treatment available for this condition